Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Petr Widimsky,
ECGs should always be read by an experienced physician and automated analysis systems of 12-lead ECG are unreliable - they commonly suggest incorrect arrhythmia diagnosis. Transesophageal ECG recordings of the atrial activity may be useful to distinguish flutter from other arrhythmias. The circumstances which have brought on the arrhythmia should be analysed. Atrial tachycardia, for example can be falsely diagnosed as flutter. Also, it may help the patient to avoid these triggering circumstances to prevent future attacks.
Atrial flutter seems to be an easy electrocardiographic (ECG) diagnosis, which can be done by a medical student. It is treated in daily practice mostly with DC cardioversion and subsequent antiarrhythmic drug use.
However, only rarely do the doctors actually analyse the circumstances which have brought on the arrhythmia. Avoiding these triggering circumstances might help in preventing future attacks. Furthermore, certain patients are referred for radiofrequency ablation (which is an effective treatment of "classical" atrial flutter), when in fact their true diagnosis is left atrial focal tachycardia - where radiofrequency ablation is substantially more difficult and provides only questionable long-term benefit.
As an introduction, I describe an example, of how atrial tachycardia (clearly triggered by external factors) was falsely diagnosed as flutter. The 53-year old normotensive male patient with no previous history of cardiac disease and a normal recent coronary CT scan was admitted for sudden onset of palpitations. He was exhausted after overnight work - he had not slept in the last 36 hours and had consumed 7 cups of coffee and 4 glasses of Coka-Cola during this period. The arrhythmia was triggered after having accidentaly swallowed an ice cube while drinking the last glass of Coke. The palpitations started precisely when the ice was passing through his oesophagus. Within 30 minutes, an ECG was recorded (fig. 1) and a full examination done. Admission blood pressure was 160/110 mmHg, his potassium level was 3,4 mmol/l, his physical examination and echocardiogram normal. The admission diagnosis was atrial flutter. The initial treatment was enoxaparine subcutaneously and propafenon intravenously. The arrhythmia was not altered by propafenon, thus DC cardioversion was planned for the next morning. Treatment was extended with intravenous potassium, magnesium and metoprolol and with oral diazepam. The patient slept for 6 hours and woke up in the early morning with a sinus rhythm. After re-discussing the ECG and the triggering moment, the arrhythmia was re-diagnosed as probable left atrial focal tachycardia, triggered by the ice passing esophagus during a "fragile period“ (stress + excess caffeine + lack of sleep). Hypokalemia and hypertension were possibly caused by stress and caffeine. The patient stopped caffeine completely, resumed more regular sleeping habits and remained asymptomatic with low blood pressure and without any further therapy.
The overall incidence of atrial flutter is 0,09% (1), 58% of patients also have atrial fibrillation in their history. Atrial flutter represents 0,1% of hospital discharges in the US, with the mean age at 67 years and male predominance cca 2:1. Case fatality is 1%, mostly related to underlying disease (1).
Any supraventricular arrhythmia can be triggered by one ore more precipitating factors: excessive caffeine intake, alcohol (either from a single excess or regular drinking), nicotin, certain drugs, hyperthyreoidism, stress, menstruation, electrolyte disturbance, hypovolemia, fever, infection or lack of sleep.
An overview of ethiologic and precipitating factors, which may trigger atrial flutter is in table 1.
Atrial flutter is a typical macro-reentrant tachycardia, i.e. the re-entry circuit occupies large areas of the atrium. Most typically, tachycardia rotates in the right atrium counter-clockwise around the tricuspid valve anulus (cavo-tricuspid isthmus – dependent flutter). Atrial rhythm is typically around 300 / min (250-350/min.)
The most frequent symptoms of atrial flutter are palpitations and/or mild chest dyscomfort. More severe symptoms (dyspnea, pre-syncope) may occur in patients with diminished reserve (e.g. left ventricular dysfunction, respiratory insufficiency etc.). Polyuria is caused by the release of atrial natriuretic peptide in response to increased atrial pressures from contractions of atria against a closed AV valve.
A surface 12-lead electrocardiogram (ECG) is frequently sufficient for diagnosis, but it may be difficult to differentiate atrial flutter from focal atrial tachycardias or other supraventricular tachycardias, which have different mechanisms and treatment. Atrial flutter usually has the atrial rate at almost precisely 300 / min. and ventricular rate most oftentimes at 150 / min. (2:1 A-V block). Vagal stimulation, adenosine or betablockers may increase the degree of A-V block and classical "flutter waves" can be visualised on the ECG as positive atrial waves in V1 and negative "sawtooth" pattern atrial waves in III, aVF (fig. 2). ECGs should always be read by an experienced physician – automated analysis systems of 12-lead ECG are unreliable and commonly suggest incorrect arrhythmia diagnosis (1). Transesophageal ECG recordings of the atrial activity may be useful to distinguish flutter from some other arrhythmias. Invasive electrophysiological examination (intracardiac ECG) is indicated usually only when connected with treatment (see below). Differential diagnosis of atrial flutter and other arrhythmias is in table 2.
DC-synchronized shock (50 J) is indicated in all urgent situations (e.g. hemodynamic compromise). The success rate is between 95-100%. Alternative non-pharmacologic treatment by atrial overdrive pacing (transvenous or transoesophageal) has a success rate of 82% and is especially used during the post-operative period in cardiac surgery. The recently published LADIP trial (3) showed a 100% success rate of radiofrequency ablation as first line treatment.
Intravenous betablockers or calcium channel blockers (dilitiazem or verapamil) slow the heart rate, but in few patients can it terminate the arrhythmia. Intravenous ibutilide converts atrial flutter to sinus rhythm in 38-76% and this occurs within cca 30 minutes (4). However, the incidence of sustained or nun-sustained ventricular tachycardia after ibutilide was up to 7%. Similar effectivity can be achieved with dofetilide. Other antiarrhythmic drugs are not significantly better than placebo: intravenous propafenone converts only 40% of atrial flutter patients, sotalol 30% and flecainide only 13%. Amiodaron is also not effective for the conversion of this arrhythmia.
Oral dofetilide has 73% efficacy for the maintenance of sinus rhythm at 1 year, while oral flecainide has 50% long-term efficacy. The experience with any oral drugs in this setting is very limited as most trials combined atrial fibrillation patients with atrial flutter patients and the former group dominated the trials. Oral betablockers or calcium channel blockers can be used effectively to slow the heart rate in cases of recurrence. Their true value for the prevention of atrial flutter recurrence was not tested in a randomised trial. Anticoagulant therapy in atrial flutter The risk of embolisation during cardioversion for atrial flutter ranges between 1,7 – 7,0%, the mean was 2,2% (1). The incidence of atrial echo-dense material or clot varies between 0 – 34% in patients with atrial flutter without anticoagulation therapy and occurs usually with > 48 hours duration of the arrhythmia. Furthermore, atrial stunning (absence of atrial contractions) was described several weeks after cardioversion in some patients. Thus, the guidelines for anticoagulation in atrial flutter should be the same as for atrial fibrillation. Cardioversion should be done only with adequate anticoagulation, or within < 48 hours after the arrhythmia onset or when transoesophageal echocardiography shows no atrial clots. Recurrent atrial flutter or even the first episode in high-risk patients with structural heart disease is indicated for long-term oral anticoagulation. A summary of therapeutic approches is in table 3.
Atrial overdrive pacing (transvenous or transoesophageal)
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Blomstrom-Lundqvist C, Scheinman MM, Antman EM, Smith SC, Priori SG, on behalf of the ACC/AHA/ESC Task Force: ACC/AHA/ESC guidelines (PDF 524 Ko) for the management of patients with supraventricular arrhythmias.
2. Granada J, Uribe W, Chiou PH. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36: 2242-6. 3. Da Costa A, Thevenin J, Roche F, Romeyer-Bouchard C, Abdellaoui L, Messier M, Denis L for the LADIP trial investigators: Results from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 2006; 114: 1676-81. 4. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-21.
Prof. P. Widimsky Prague, Czech Republic Chairman of the ESC credentials Committee
© 2017 European Society of Cardiology. All rights reserved